{"id":"lentinan","rwe":[],"tags":[{"label":"lentinan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L03AX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"biomoduline","offLabel":[],"synonyms":["lentinan","biomoduline"],"timeline":[],"approvals":[],"brandName":"Biomoduline","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"lentinan","explanation":"Think of Biomoduline like a key that unlocks the immune system's natural defense mechanisms. When taken, it helps the body produce more interferon, which then helps to fight off invading pathogens and diseases. This can help the body recover from illness and infection more quickly.","oneSentence":"Biomoduline works by stimulating the immune system to produce more interferon, a protein that helps fight off infections and diseases.","technicalDetail":"Biomoduline acts as an immunomodulator, specifically activating the Toll-like receptor 4 (TLR4) pathway, which leads to the production of interferon and other cytokines that stimulate the immune response."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2987","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LENTINAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LENTINAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:17:17.632066","biosimilars":[],"competitors":[{"drugName":"pegademase","drugSlug":"pegademase","fdaApproval":"1990-03-21","relationship":"same-class"},{"drugName":"glatiramer acetate","drugSlug":"glatiramer-acetate","fdaApproval":"1996-12-20","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plerixafor","drugSlug":"plerixafor","fdaApproval":"2008-12-15","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elapegademase","drugSlug":"elapegademase","fdaApproval":"2018-10-05","relationship":"same-class"}],"genericName":"lentinan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pegademase","brandName":"pegademase","genericName":"pegademase","approvalYear":"1990","relationship":"same-class"},{"drugId":"glatiramer-acetate","brandName":"glatiramer acetate","genericName":"glatiramer acetate","approvalYear":"1996","relationship":"same-class"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-class"},{"drugId":"plerixafor","brandName":"plerixafor","genericName":"plerixafor","approvalYear":"2008","relationship":"same-class"},{"drugId":"elapegademase","brandName":"elapegademase","genericName":"elapegademase","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00677027","phase":"PHASE1","title":"Dose Escalation Safety Study of MM-10-001 in Healthy Subjects","status":"UNKNOWN","sponsor":"GlycaNova Norge AS","startDate":"2008-02","conditions":["Healthy"],"enrollment":50,"completionDate":"2008-06"},{"nctId":"NCT00002099","phase":"PHASE2","title":"Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients","status":"UNKNOWN","sponsor":"AJI Pharma USA","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002098","phase":"PHASE1","title":"Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients","status":"COMPLETED","sponsor":"AJI Pharma USA","startDate":"","conditions":["HIV Infections"],"enrollment":50,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"6751655D1D","CHEBI":"CHEBI:31770","UMLSCUI":"C0023324","ChEMBL_ID":"CHEMBL2108209","KEGG_DRUG":"D01695","DRUGBANK_ID":"DB13480","PUBCHEM_CID":"37723","MESH_DESCRIPTOR_UI":"D007912"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":755,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AX01","allCodes":["L03AX01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Biomoduline (LENTINAN) is a small molecule drug belonging to the lentinan class. It is a polysaccharide derived from the Lentinula edodes mushroom, originally developed by and currently owned by. Biomoduline is used to stimulate the immune system, but its exact target and approved indications are unknown. Its commercial status and key safety considerations are not well-documented.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}